'Compliance programs' diaporamas de présentation

Expanded Coverage through the Affordable Care Act: What it Means to You and Your Business

Expanded Coverage through the Affordable Care Act: What it Means to You and Your Business. Integra Users Seminar January 23, 2014 Leigh Davitian , JD Brad Kile, PhD. Disclosures. Brad Kile is an independent consultant and has no financial interest or relationships to disclose .

1.06k views • 97 slides

Integration of Compliance Management into Organizational Performance

Integration of Compliance Management into Organizational Performance. Deborah Randall, Esq. law@deborahrandallconsulting.com www.deborahrandallconsulting.com. I. Why Develop An Internal Corporate Compliance Program?.

1.1k views • 95 slides

616 views • 47 slides

Part 2: The Compelling Display of Compliance Data

Part 2: The Compelling Display of Compliance Data. Robert Emery, DrPH, CHP, CIH, CSP, RBP, CHMM, CPP, ARM Assistant Vice President for Safety, Health, Environment & Risk Management The University of Texas Health Science Center at Houston Associate Professor of Occupational Health

859 views • 44 slides

Privacy, Security and Compliance Concerns for Management and Boards November 15, 2013 Carolyn Heyman-Layne, Esq.

Privacy, Security and Compliance Concerns for Management and Boards November 15, 2013 Carolyn Heyman-Layne, Esq. Covering the Basics. HIPAA 42 CFR Part 2 Other potential privacy laws: Privacy Act, FERPA, AK PIPA, other State laws

578 views • 35 slides

DSM Environmental Services, Inc .

DSM Environmental Services, Inc. E NVIRONMENTAL P ROGRAM M ANAGEMENT S ERVICES CAPABILITIES PRESENTATION. DSM E NVIRONMENTAL P ROGRAM M ANAGEMENT S ERVICES. E NVIRONMENTAL P ROGRAM M ANAGEMENT 1. W HAT I S P ROGRAM M ANAGEMENT ?

419 views • 29 slides

Emerging Pharmaceutical Industry Strategies: Transparency, Privacy and COI Concerns

Emerging Pharmaceutical Industry Strategies: Transparency, Privacy and COI Concerns. Jennifer L. Reck, Policy Analyst, Prescription Policy Choices. NLARx Meeting Washington, DC December 8, 2008. Prescription Policy Choices.

472 views • 18 slides

Solvent Recycling in an Academic Research Laboratory

Solvent Recycling in an Academic Research Laboratory Steve Brehio Northeastern University Office of Environmental Health & Safety Boston, Massachusetts Northeastern University National research university located in Boston, Massachusetts World leader in practiced-orientated education

603 views • 17 slides

Evaluation of Research and Compliance Plans

Evaluation of Research and Compliance Plans. Christine C. Boesz, Dr.P.H. Inspector General National Science Foundation, USA INORMS Brisbane, Australia August 24, 2006. Accountability: Who Cares?????. Taxpayers Appropriators $$$$ (e.g., US Congress) Funding Agencies

289 views • 16 slides

Compliance Alliance Networking Briefing May 3, 2012

Compliance Alliance Networking Briefing May 3, 2012. Raising Company-Wide Support For Your Compliance Operations. Raising Company-Wide Support Durand - Profile. Degree: -M.B.A. University of Massachusetts Trade Compliance Certifications:

244 views • 16 slides

Overview of CVM Bioresearch Monitoring

Overview of CVM Bioresearch Monitoring. Vernon D. Toelle, Ph.D. Team Leader Pre-Market Compliance and Administrative Actions Team (BIMO Team). Bioresearch Monitoring (BIMO).

262 views • 14 slides

DDTC AUDITS & TIPS FOR COMPLIANCE READY PROGRAMS

298 views • 14 slides

FDA Regulatory & Compliance Symposium Special Pre-Conference Workshop August 24, 2005

279 views • 14 slides

CICA Top 10 Survey

401 views • 13 slides

247 views • 13 slides

Inspection Of Compliance Programs for High Risk Areas

Inspection Of Compliance Programs for High Risk Areas. September 21, 2001 Sharon Corum, CPA. Inspection: An examination aimed at forming a judgment or evaluation of high-risk compliance programs. Communication of Inspection Results:.

260 views • 10 slides

IMPLICATIONS OF MPDIMA ON PHARMACEUTICAL COMPLIANCE PROGRAMS

IMPLICATIONS OF MPDIMA ON PHARMACEUTICAL COMPLIANCE PROGRAMS. Scott Willoughby Ernst & Young February 27, 2004. IMPLICATIONS OF MPDIMA ON PHARMACEUTICAL COMPLIANCE PROGRAMS.

185 views • 9 slides

Background Investigations

The Turner Group is helping its clients with services like integrity monitoring, pre-employment screening, physical forensics

183 views • 8 slides

Steve Mohr, Esq. Deputy Compliance Officer AstraZeneca Pre-Conference Co-Chair

Current Issues in Pharmaceutical and Medical Device Compliance Management Introductory Comments Pharma, Medical Device & Biotech Colloquium June 6, 2005. Steve Mohr, Esq. Deputy Compliance Officer AstraZeneca Pre-Conference Co-Chair. Overview

193 views • 8 slides

2nd Largest Privately Owned Truckload Carrier Gives Source I

U.S. Xpress Enterprises, Inc. is the latest global brand to entrust Source Intelligence

89 views • 2 slides